Gene · 3745
KCNB1: potassium voltage-gated channel subfamily B member 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNB1: potassium voltage-gated channel subfamily B member 1. Genes, record 3745. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3745
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14721 | Potassium voltage-gated channel subfamily B member 1 | 858 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58754 | Q14721 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9245 | Q14721 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2195 | Q14721 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2195 | Q14721 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9245 | Q14721 | Espacenet |
| US 11673916 B2 | 2023-06-13 | 41 | Q14721 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65827 | Q14721 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65828 | Q14721 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 3182 | Q14721 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 168798 | Q14721 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
Trials86
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 86
See all 86 trialsNIH grants1,129
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNB1 papers | Newest fiscal year |
|---|---|---|---|
| T32HL086350 | Training Program in Basic and Translational Cardiovascular Science | 6 | 2025 |
| ZIANS002945 | Gating mechanisms and pharmacology of voltage-activated ion channels | 6 | 2025 |
| U24NS109113 | Molecularly Defined Immunoprobes for Scalable Brain Protein Mapping with Reference Datasets | 4 | 2025 |
| R01GM030376 | The Electrophysiological Studies of Voltage Gated Channels | 3 | 2025 |
| R01NS107671 | Therapeutic small molecule modulation of Kv channels | 3 | 2025 |
| U24NS120854 | ClinGen Expert Curation Panel for the Epilepsies | 3 | 2025 |
| UL1TR001878 | Institutional Clinical and Translational Science Award | 3 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30EY003176 | UC Berkeley Vision Science CORE | 2 | 2025 |
1 to 10 of 1,129Source NIH's project files
See all 1,129 nih grantsPapers1,741
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Modulation of voltage-dependent K+ channel activity by the muscarinic receptor antagonist solifenacin in native coronary arterial smooth muscle cells. | Korean J Physiol Pharmacol | 2026 | 42733228 | PubTator, text mining | PubMed |
| Epileptic encephalopathy-related Kv2.1 mutants impair clustering but not neuronal excitability. | Biophys J | 2026 | 42717490 | PubTator, text mining | PubMed |
| Tunable Chemical and Optical Modulation of ER-Plasma Membrane Contact-Site Geometry, Dynamics, and Protein Recruitment with High-Fidelity Visualization. | Anal Chem | 2026 | 42674029 | PubTator, text mining | PubMed |
| Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial. | EBioMedicine | 2026 | 42531722 | PubTator, text mining | PubMed |
| Building structure activity relationships to avoid toxicity due to unwanted central nervous system ion channel activity. | Toxicol Sci | 2026 | 42530889 | PubTator, text mining | PubMed |
| Electrophysiological Characterization of MK886-Mediated Suppression of Voltage-Gated K+ Currents in Rabbit Coronary Artery Smooth Muscle Cells. | J Appl Toxicol | 2026 | 42487466 | PubTator, text mining | PubMed |
| Ancestry-informative regulatory variants at KCNB1 modulate adipogenesis and body mass index. | Front Endocrinol (Lausanne) | 2026 | 42181176 | PubTator, text mining | PubMed |
| Unveiling sleep disturbances in KCNB1-related disorders: Insights from a cohort of 78 individuals. | Epilepsia Open | 2026 | 42166541 | PubTator, text mining | PubMed |
| Distinct mechanisms of inhibition of Kv2 potassium channels by tetraethylammonium and RY785. | Elife | 2026 | 42043292 | PubTator, text mining | PubMed |
| Potassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies. | Curr Neuropharmacol | 2026 | 42003125 | PubTator, text mining | PubMed |
1 to 10 of 1,741
See all 1,741 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3745
GET https://conductscience.org/api/genes/v1/3745/patents?page=2